The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit

• David A. Wohl ,

  * E-mail: wohl@med.unc.edu

  Affiliation University of North Carolina, Chapel Hill, North Carolina, United States of America

  ⨯
• Michelle A. Kendall,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Judith Feinberg,

  Affiliation University of Cincinnati, Cincinnati, Ohio, United States of America

  ⨯
• Beverly Alston-Smith,

  Affiliation Division of AIDS, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Susan Owens,

  Affiliation Frontier Science & Technology Foundation, Amherst, New York, United States of America

  ⨯
• Suzette Chafey,

  Affiliation University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Michael Marco,

  Affiliation Columbia University, New York, New York, United States of America

  ⨯
• Sharon Maxwell,

  Affiliation University of Washington, Seattle, Washington, United States of America

  ⨯
• Constance Benson,

  Affiliation University of California San Diego, San Diego, California, United States of America

  ⨯
• Philip Keiser,

  Affiliation University of Texas – Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Charles van der Horst,

  Affiliation University of North Carolina, Chapel Hill, North Carolina, United States of America

  ⨯
• Mark A. Jacobson,

  Affiliation University of California San Francisco, San Francisco, California, United States of America

  ⨯
• for the A5030 Study Team